Abstract:Aim: To observe the therapeutic efficacy and prognostic factors that influence survival rates in non-small cell lung cancer (NSCLC) patients with multiple brain metastases (BMs), (more than three and less than ten).Methods: Retrospective analyses were conducted on the clinical data of 209 NSCLC patients with multiple BMs and were admitted to our hospital between March 2007 and November 2012. All BM patients received whole-brain radiotherapy. Two hundred patients received combined chemotherapy during the treatment process; 99 received targeted drug therapy; and nine got only symptomatic and supportive treatment. Survival time was defined as the period from the start of BM therapy to the patient's death or end of the follow-up period. The Kaplan-Meier method was used to calculate the median survival time, and the 6-month, 1-, and 2-year cumulative survival rates, as well as to plot the survival curves. The patients' cultural background included their socioeconomic status, level of education, their understanding of the disease, and the degree of care and support they received from their family members. Log-rank test was employed to test the differences in the survival rates between the subgroups. Cox multivariate regression analyses were used to analyze the various factors influencing the prognoses of NSCLC with multiple BMs.Results: The follow-up duration was between 1 and 87 months. The median survival time for all BM patients was 12.1 months (95% confidence interval 9.37-14.83). The 6-month, 1-, and 2-year cumulative survival rates were 80%, 50.2%, and 10.7%, respectively. Univariate analyses revealed that the independent factors influencing survival prognoses included Karnofsky Performance Status score, control of the primary lung tumor, interval between the confirmed diagnoses of lung cancer and BM, presence of extracranial metastasis, number of chemotherapy cycles undergone, Graded Prognostic Assessment class, administration of combined targeted drug therapy, the pathological type, and the cultural backgrounds of the patients. Multivariate analyses indicated that the number of chemotherapy cycles, administration of combined drug therapy, and patients' cultural background were key independent factors influencing survival prognoses.Conclusion: Active treatment of NSCLC with multiple BMs was beneficial, and the patients' cultural background had a strong influence on survival prognoses. Chemotherapy combined with targeted drug therapy could increase the patients' median and overall survival rates. The number of chemotherapy cycles undergone, administration of combined targeted drug therapy, and the cultural backgrounds of the patients had significant effects on the patients' survival prognoses.

Metachronous Brain Metastasis in Patients with EGFR-mutant NSCLC Indicates a Worse Prognosis.

Risk Factors of Metachronous Brain Metastasis in Patients with EGFR-mutated Advanced Non-Small Cell Lung Cancer

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Clinicopathological characteristics and prognosis of synchronous brain metastases from non-small cell lung cancer compared with metachronous brain metastases

Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer

Outcomes of EGFR, ALK, ROS1, BRAF, MET, and RET mutated non-small cell lung cancer with brain metastases (NSCLC BM).

Mutational Signatures of Synchronous and Metachronous Brain Metastases from Lung Adenocarcinoma

Epidemiology and survival outcomes of synchronous and metachronous brain metastases: a retrospective population-based study

Analyses of Prognostic Factors in Cases of Non-Small Cell Lung Cancer with Multiple Brain Metastases

[Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis].

Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases

Outcomes of 27 Non-Small Cell Lung Cancer Patients Receiving Resections of Paired Primary Pulmonary and Brain Metastatic Tumours: Is EGFR Negative Mutation of Brain Metastasis Bring More Benefit?

A real-world study in advanced non-small cell lung cancer with de novo brain metastasis

P3.02b-076 Bisphosphonates Enhance Effect of EGFR-TKIs in NSCLC Patients with EGFR Mutation and Bone Metastases

Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses.

EGFR TKIs Plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases

EGFR-TKIs Plus Bevacizumab Demonstrated Survival Benefit Than EGFR-TKIs Alone in EGFR-mutant NSCLC Patients with Multiple Brain Metastases

EPID-01. ANTINEOPLASTIC, RADIATION, AND SYNCHRONICITY EFFECTS ON BRAIN METASTASIS SURVIVAL: A RETROSPECTIVE POPULATION-BASED STUDY

The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis

Prognosis of Different Bone Metastases Patterns in EGFR-mutant Advanced Lung Adenocarcinoma Patients

Early Radiation Therapy Combined with Egfr-Tki is Associated with Longer Survival in Egfr-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases